Skip to content
Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma

Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma

Get the podcast

An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New

The Audio Journal of Oncology

An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York.

Sarah Maxwell, Audio Journal of Oncology:

“An exciting, new immunotherapy treatment for multiple myeloma, was under discussion at the 2024 American Association for Cancer Research Annual Meeting, held in San Diego. It was with a drug that targets not one but two cells to fight the disease.

The agent, linvoseltamab, is a B-cell maturation antigen-targeted, T-cell-engaging, bispecific antibody. A multi-center international study, reported at the conference that patients with relapsed or refractory multiple myeloma, had robust clinical benefit from treatment with the drug. And that included those in difficult-to-treat subgroups.

After giving his talk in San Diego, lead author Sundar Jagannath, Director of the Center of Excellence for Multiple Myeloma, at Mount Sinai in New York, gave the Audio Journal of Oncology more details on the therapeutic benefits the drug offers. He began by talking about where this new approach fits into the landscape and history of treatments for multiple myeloma:

Audio Journal of Oncology interview with: Sundar Jagannath MBBS, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York.

IN: I’ve been in the field of multiple myeloma….…

OUT: ….in New York. I’m Peter Goodwin.

15:43”

AACR Abstract Title:

Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups

https://www.abstractsonline.com/pp8/#!/20272/presentation/11419

Next in AACR 2024

All 4 interviews

Interview 4 of 4

Olivier Lantz MD PhD; AACR 2024: Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers

Olivier Lantz MD PhD; AACR 2024: Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers

An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that

9 April 2025
14 min

Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

10 Nov 2026
10 min
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca

21 May 2026
11 min